JP2010509233A5 - - Google Patents

Download PDF

Info

Publication number
JP2010509233A5
JP2010509233A5 JP2009535482A JP2009535482A JP2010509233A5 JP 2010509233 A5 JP2010509233 A5 JP 2010509233A5 JP 2009535482 A JP2009535482 A JP 2009535482A JP 2009535482 A JP2009535482 A JP 2009535482A JP 2010509233 A5 JP2010509233 A5 JP 2010509233A5
Authority
JP
Japan
Prior art keywords
alkyl
methyl
methylamino
triazin
cyclohexanecarboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009535482A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010509233A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/083449 external-priority patent/WO2008105968A1/en
Publication of JP2010509233A publication Critical patent/JP2010509233A/ja
Publication of JP2010509233A5 publication Critical patent/JP2010509233A5/ja
Withdrawn legal-status Critical Current

Links

JP2009535482A 2006-11-03 2007-11-02 新規sEH阻害剤およびそれらの使用 Withdrawn JP2010509233A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86417806P 2006-11-03 2006-11-03
PCT/US2007/083449 WO2008105968A1 (en) 2006-11-03 2007-11-02 Novel seh inhibitors and their use

Publications (2)

Publication Number Publication Date
JP2010509233A JP2010509233A (ja) 2010-03-25
JP2010509233A5 true JP2010509233A5 (enExample) 2011-01-06

Family

ID=39721528

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009535482A Withdrawn JP2010509233A (ja) 2006-11-03 2007-11-02 新規sEH阻害剤およびそれらの使用

Country Status (4)

Country Link
US (1) US7994317B2 (enExample)
EP (1) EP2097378B1 (enExample)
JP (1) JP2010509233A (enExample)
WO (1) WO2008105968A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008483B2 (en) 2007-10-11 2011-08-30 GlaxoSmithKline, LLC sEH inhibitors and their use
ES2445444T3 (es) 2007-10-11 2014-03-03 Glaxosmithkline Llc Nuevos inhibidores de sEH y su uso
US20120295911A1 (en) 2010-11-29 2012-11-22 Galleon Pharmaceuticals, Inc. Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases
AU2011336764B2 (en) 2010-11-29 2017-02-23 Galleon Pharmaceuticals, Inc. Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases
WO2014111465A1 (en) 2013-01-17 2014-07-24 Sanofi Isomannide derivatives as inhibitors of soluble epoxide hydrolase
WO2016012623A1 (en) * 2014-07-25 2016-01-28 Theravectys Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule
US20200317813A1 (en) 2016-05-25 2020-10-08 Johann Wolfgang Goethe-Universitat Frankfurt Am Main Treatment and diagnosis of non-proliferative diabetic retinopathy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
EP1464335A3 (en) 2003-03-31 2007-05-09 Taisho Pharmaceutical Co. Ltd. Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist
US8008483B2 (en) 2007-10-11 2011-08-30 GlaxoSmithKline, LLC sEH inhibitors and their use
ES2445444T3 (es) 2007-10-11 2014-03-03 Glaxosmithkline Llc Nuevos inhibidores de sEH y su uso
US20100210655A1 (en) 2007-10-11 2010-08-19 Yun Ding NOVEL sEH INHIBITORS AND THEIR USE

Similar Documents

Publication Publication Date Title
JP2010509233A5 (enExample)
JP2007519754A5 (enExample)
RU2386630C2 (ru) Соединения и композиции в качестве ингибиторов протеинтирозинкиназы
RU2004102397A (ru) Применение антагонистов рецептора nk-1 для лечения черепно-мозговой и спинномозговой травмы или повреждения нервной ткани
RU2009118254A (ru) Фенилацетамиды в качестве ингибиторов протеинкиназ
RU2020108515A (ru) Соединения и способы целевого расщепления андрогенного рецептора
JP2005526723A5 (enExample)
NO2017065I1 (no) Kombinasjon av rilpivirine-hydroklorid eller terapeutisk ekvivalent derav og tenofovir, spesielt tenofovir disproksil fumarat
JP2016503786A5 (enExample)
JP2009542716A5 (enExample)
CN1428145A (zh) 用作速激肽nk3受体拮抗剂的喹啉衍生物
JP2010538076A5 (enExample)
JP2006510609A5 (enExample)
NO2014032I1 (no) (E)-4-[[4-[[4-(2-cyanoetenyl)-2,6-dimetylfenyl-amino]--2-pyrfmidinyl]-amino]-benzonitril Rilpivirine) samt enhver terapeutisk ekvivalent form derav som er beskyttet av det aktuelle patentet så som farmasøytisk akseptable salter innbefattende hydrokloridsaltet av Rilpiverine; tenofovir og spesielt tenofovirdisproksilfumatat og emtricitabine.
RU2004117156A (ru) Амид замещенные имидазопиридины
JP2018522823A5 (enExample)
JP2010504342A5 (enExample)
JP2003502405A5 (enExample)
CA2556944A1 (en) Thiazole derivative
JP2013537887A5 (enExample)
RU2005136655A (ru) Производные пиримидина, пригодные для лечения болезней, опосредованных сrth2
CA2415486A1 (en) Pyramidine derivatives
JP2008501800A5 (enExample)
JP2002053555A5 (enExample)
JP2004529931A5 (enExample)